About Biofourmis
What Biofourmis is building
Technologies used at Biofourmis
C
C++
Python
Linux
GitCompany culture
Make a Difference
Improve outcomes for patients around the world
Cutting-edge Innovation
Change how and where healthcare is delivered with ground-breaking technology
Funding rounds
Total Funding
Last funding round type
Company type
Biofourmis news and updates
Biofourmis launches Biofourmis Care technology-enabled care management service for health care systems
Biofourmis has launched its Biofourmis Care technology-enabled care management service for health care systems and health plans that delivers remote care for individuals with chronic conditions.
Jan 1, 2022 | openminds.comBiofourmis signed new client Blessing Health on Mar 30th 22'.
Biofourmis, a Boston -based global leader in virtual care and digital therapeutics, today announced that it was selected by Blessing Health System in Quincy, Ill., as the technology solutions partner for its newest program, which delivers acute-level hospital care inside patients' homes.
Jan 1, 2022 | prnewswire.comBlessing Health partners with Biofourmis
Blessing Health System will work with Biofourmis to deliver at-home care.
Jan 1, 2022 | mhealthintelligence.comGeneral Atlantic invested into Biofourmis in $300M on Apr 26th 22'.
Biofourmis, a Singapore founded and now US-based operator of a health analytics platform, has achieved unicorn status with the closing of a USD 300m Series D round led by General Atlantic.
Jan 1, 2022 | avcj.comBiofourmis hires Omar Ishrak as chairman
Biofourmis also announced that medtech veteran Omar Ishrak is joining the company’s board as its chairman.
Jan 1, 2022 | informa.comBiofourmis received financing of $10M in funding on Apr 26th 19'.
(Biofourmis) Three years ago, technology startup Biofourmis had raised $10 million in total funding.
Jan 1, 2022 | fiercehealthcare.comBiofourmis receives financing of $445M in funding
To date, Biofourmis has raised a total of $445 million in funding.
Jan 1, 2022 | technode.globalBiofourmis received financing of $300M in Series D investment on Apr 26th 22'.
Biofourmis, a global leader in virtual care and digital medicine, today announced it has surpassed unicorn status with a $300 million Series D investment led by leading global growth equity firm General Atlantic.
Jan 1, 2022 | yahoo.comBiofourmis received financing of $100M in round on Sep 1st 20'.
Biofourmis' last funding round came in September 2020, when it scooped up $100 million in Series C funding.
Jan 1, 2022 | mobihealthnews.comBiofourmis expanded offices to United States on Jan 1st 19'.
Originally based in Singapore, Biofourmis moved its headquarters to the United States in 2019.
Jan 1, 2022 | forbes.comSOFTBANK INVESTMENT Advisers invested into Biofourmis in $100M on Sep 1st 20'.
Biofourmis had previously raised a $100 million round in September 2020 led by SoftBank Investment Advisers at an undisclosed valuation.
Jan 1, 2022 | forbes.comBiofourmis receives financing of $27M in equity funding
Healthtech unicorn Biofourmis received nearly $27 million in equity funding last week as part of a $300 million Series D round announced in April.
Jan 1, 2022 | dealstreetasia.comBiofourmis signed new client American College of Cardiology on May 12th 22'.
Biofourmis, a Boston -based global leader in virtual care and digital medicine, announced today that its Biofourmis Care solution has been selected by the American College of Cardiology (ACC) for its TRANSFORM 3 study that will evaluate different intervention strategies for improving adherence to guideline-directed medication therapy (GDMT) for managing chronic cardiovascular conditions.
Jan 1, 2022 | prnewswire.comCVS Health Corporation invests into Biofourmis in $300M
Biofourmis, a health technology developer specializing in digital medicine and virtual care solutions, has landed $300m USD in a Series D investment round, with contributors including CVS Health.
Jan 1, 2022 | outsourcing-pharma.comCVS Health Corporation invests into Biofourmis in $300M
Biofourmis, a health technology developer specializing in digital medicine and virtual care solutions, has landed $300m USD in a Series D investment round, with contributors including CVS Health.
Jan 1, 2022 | outsourcing-pharma.comWise Health System partners with Biofourmis
Decatur, Texas-based Wise Health System has partnered with AI-powered remote patient monitoring company Biofourmis to launch a hospital-at-home program.
Jan 1, 2022 | beckershospitalreview.comBiofourmis launches continuum-wide care-at-home initiative
Biofourmis, a Boston-based global leader in virtual care and digital medicine, has announced its engagement with Wise Health System to launch a continuum-wide care-at-home initiative.
Jan 1, 2022 | homecaremag.comBiofourmis receives financing of $20M in Series D financing
Biofourmis, a Boston, MA-based global leader in virtual care and digital medicine, raised an additional USD20m in Series D financing.
Jan 1, 2022 | finsmes.comIntelcapital invests into Biofourmis in $20M
Intel Capital invests $20 million in analytics-powered virtual care company Biofourmis, extending its Series D round to a final $320 million.
Jan 1, 2022 | histalk2.comBiofourmis launched Care at Home platform for treating heart failure, atrial fibrillation, diabetes and hypertension on Feb 1st 22'.
In February, Biofourmis unveiled its Care at Home platform for treating heart failure, atrial fibrillation, diabetes and hypertension.
Jan 1, 2022 | axios.comBiofourmis Named 2021 DPHARM Idol Disrupt Winner
Biofourmis, a Boston-based global leader in digital therapeutics and virtual care that powers personalized predictive care, has been named the winner of the 2021 DPHARM Idol Disrupt event.
Oct 11, 2021 | PR NewswireHospitals, Health Systems Hungry for Partnerships with At-Home Care Enablers
The hospital-at-home concept was pioneered over two decades ago at Johns Hopkins. It became in vogue during the earlier parts of the COVID-19 crisis.
Sep 29, 2021 | Home Health Care NewsBiofourmis Earns FDA's First-Ever Breakthrough Device Designation for a Novel Digital Therapeutic for Heart Failure
Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced today its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Jul 29, 2021 | PR NewswireBiofourmis partners with Yale Computer Graphics Group
Biofourmis, a fast-growing global leader in digital therapeutics, has entered a research partnership with the Yale University -Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI).
Jan 1, 2019 | biofourmis.com